OSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR) Files An 8-K Other Events

OSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR) Files An 8-K Other Events
Item 9.01. Other Events.

Story continues below

On September17, 2018, Osiris Therapeutics,Inc. (the “Company”) issued a press release announcing the launch of GrafixPL PRIME™, the Company’s first ambient temperature stable placental membrane product, beginning on October1, 2018. A copy of the Company’s press release is attached hereto as Exhibit99.1 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


OSIRIS THERAPEUTICS, INC. Exhibit
EX-99.1 2 a18-31033_1ex99d1.htm EX-99.1 Exhibit 99.1   Osiris Therapeutics,…
To view the full exhibit click here

About OSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR)

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

An ad to help with our costs